placebo + exenatide
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus
Conditions
Diabetes Mellitus
Trial Timeline
Aug 1, 2008 → Jan 1, 2012
NCT ID
NCT00701935About placebo + exenatide
placebo + exenatide is a phase 2 stage product being developed by Eli Lilly for Diabetes Mellitus. The current trial status is terminated. This product is registered under clinical trial identifier NCT00701935. Target conditions include Diabetes Mellitus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00765817 | Phase 3 | Completed |
| NCT00701935 | Phase 2 | Terminated |
Competing Products
20 competing products in Diabetes Mellitus